Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company dedicated to advancing therapeutics for neurodegenerative diseases, has announced that Will Chou, M.D., the company's president and CEO, will engage in a fireside chat at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. This event is scheduled for Wednesday, November 12, 2025, at 9:30 a.m. ET in Boston, MA. Participants and investors can access a live webcast via the Investors & News section of Passage Bio’s official website, with a replay available for 90 days post-event.

Passage Bio is driven by a mission to enhance the lives of patients grappling with debilitating neurodegenerative conditions through the innovation of one-time genetic therapies. The company is currently focused on its lead product candidate, PBFT02, which aims to address frontotemporal dementia (FTD) specifically by raising levels of progranulin, a protein essential for lysosomal function. This therapeutic approach seeks to mitigate disease progression, marking a pivotal step in treating neurological disorders that have long evaded effective solutions.

With a strong commitment to developing transformative treatments, Passage Bio underscores its dedication to protecting patients and families against the often devastating consequences of neurodegenerative diseases. For further inquiries, investors and media representatives can reach out to Stuart Henderson via email for investor relations or Mike Beyer for media communications. As it prepares to present at this prestigious healthcare conference, Passage Bio aims to raise awareness and garner interest in its groundbreaking therapeutic advancements for neurodegenerative diseases. For more detailed information about the company and its ongoing projects, interested parties are encouraged to visit their website at passagebio.com.

As Passage Bio prepares to present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on November 12, 2025, investors should closely monitor the company’s developments, especially in light of its unique focus on treatments for neurodegenerative diseases. The participation of Will Chou, M.D., the CEO, highlights the company’s commitment to advancing its innovative therapies, particularly PBFT02, which aims to address conditions like frontotemporal dementia through elevation of progranulin levels.

Investors should consider the broader market landscape for genetic medicines, where there is significant potential given the increasing incidence of neurodegenerative diseases and the growing demand for novel therapies. Passage Bio's unique approach to targeting the underlying pathologies of these conditions places it in a promising position within a competitive market. As a clinical-stage company, progress in clinical trials and data announcements will be key drivers of stock performance.

The upcoming conference offers an excellent platform for the company to articulate its strategy and ongoing research outcomes, which could bolster investor sentiment or clarify its path forward. It's also an opportunity for market analysts to gain insights into the company’s pipeline and alignment with industry trends.

Investors should watch for updates post-conference, particularly regarding any clinical milestones or collaborations that may be discussed. Given the current valuations in the biotech sector, Passage Bio could represent an attractive buy for long-term investors, particularly if there is momentum from the conference that leads to increased visibility and confidence in the company’s leading therapeutic approaches. However, due diligence is advised, as with any investment in early-stage biotech firms, given the inherent risks associated with clinical development.